Berger A, et al. - In order to determine the incidence and cost of both major adverse cardiovascular events (MACE, defined as myocardial infarction, stroke, or cardiovascular-related death) and major adverse limb events (MALE, critical limb ischemia, amputation, or peripheral artery disease-related revascularization) in patients with coronary artery disease (CAD) or peripheral artery disease (PAD), researchers used a database with healthcare claims linked to electronic medical records. Of 99,730 eligible patients, CAD was present in 86.0%, PAD in 25.8%, and both in 11.8%. The participants had a mean (±standard deviation) age of 67.7 (±11.5) years and 59.8% were male. In patients who suffered MACE or MALE, $44,495 greater adjusted 1-year healthcare costs were reported. Within about 2 years of follow-up, additional MACE or MALE occurred in nearly 1 in 7 patients with chronic CAD or PAD; the demand for new secondary prevention therapies was highlighted by the comparatively high risk and cost of these events.